Methods and compositions for cancer treatment
US-2024424094-A1 · Dec 26, 2024 · US
US10258672B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10258672-B2 |
| Application number | US-201615274236-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 23, 2016 |
| Priority date | Oct 9, 2014 |
| Publication date | Apr 16, 2019 |
| Grant date | Apr 16, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A method of treating root avulsion injury in a subject in need thereof includes administering to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of PTPσ.
Opening claim text (preview).
Having described the invention, we claim: 1. A method of treating root avulsion injury in a subject in need thereof, the method comprising: administering to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of PTPσ, wherein the therapeutic agent comprises a therapeutic peptide, the therapeutic peptide including an amino acid sequence selected from the group consisting of SEQ ID NO: 32 and SEQ ID NO: 63. 2. The method of claim 1 , the therapeutic agent comprising a therapeutic peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 32 and SEQ ID NO: 63. 3. The method of claim 1 , wherein the therapeutic agent includes a transport moiety that is linked to the therapeutic peptide and facilitates uptake of the therapeutic peptide by a nerve cell being treated. 4. The method of claim 3 , wherein the transport moiety is an HIV Tat transport moiety. 5. The method of claim 3 , wherein the therapeutic agent is administered systemically to the subject being treated. 6. The method of claim 1 , further comprising connecting an avulsed end in a peripheral nerve to a portion of the central nervous system. 7. The method of claim 1 , wherein the therapeutic agent is administered at an amount effective to increase survival rate of injured motoneurons, enhance regrowth across inhibitory central nervous system scar into re-implanted spinal roots, regenerate axons, decrease muscle atrophy, and/or promote motor functional recovery.
Protein-tyrosine-phosphatase (3.1.3.48) · CPC title
Cytokines; Lymphokines; Interferons · CPC title
Enzyme inhibitors (protease inhibitors A61K38/55) · CPC title
acting on ester bonds (3.1), e.g. lipases, ribonucleases · CPC title
Antigen-pulsed cells, e.g. T-cells · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.